healthcare

Going to pot: Why cannabis could be Asia's darling bud

As governments across Asia explore the upside of legalising medicinal marijuana and China expands its already substantial hemp production capabilities, major players in the fast-growing international cannabis economy see the region as a key emerging market.
January 30, 2019

Gene sequencing company raises $200m

With the debate about gene-edited babies raging, it is a sensitive time for Wuxi NextCODE to announce the completion of Series C funding.
November 29, 2018

Innovent Biologics’ HK IPO sells long-term value

The drug developer will be the second biotech firm to list in Hong Kong without any profits or revenues. It believes that China’s underpenetrated biologics market provides a massive opportunity in the long run.
October 18, 2018

GIC makes another bet on Chinese pharma

Singapore’s state fund leads $85 million funding for Harbour BioMed, marking its third investment in the Chinese pharmaceutical space in four months.
August 27, 2018

China Biologic's ex-CEO throws his hat in the ring

Former chief of the Nasdaq-listed biotechnlogy firm launches a $3.9 billion bid to take it private. His consortium of backers face a potential battle to bring back ownership to China.
August 21, 2018